标准解读

GB 29922-2013食品安全国家标准《特殊医学用途配方食品通则》是针对特殊医学用途设计的食品制定的一套国家标准。这项标准旨在确保此类食品在满足特定疾病或医疗状况人群的营养需求同时，保障其食用安全。下面是该标准的主要内容概述：

  1. 适用范围：明确了本标准适用于为满足特定疾病状态或医疗状况下人群对营养素或膳食管理的特殊需要，专门加工配制而成的食品。这包括全营养配方食品、特定全营养配方食品以及非全营养配方食品三大类。

  2. 定义与分类：详细界定了特殊医学用途配方食品的定义，并根据营养成分的全面性及目标使用人群的特定需求，将其分为不同的类型，每种类型有其特定的营养配置要求。

  3. 原料要求：规定了用于生产特殊医学用途配方食品的原料必须符合国家相关食品安全标准，确保无污染、无过敏源风险（除非产品特性所需），并要求明确标示所有原料成分。

  4. 营养成分及含量：设定了各类特殊医学用途配方食品应含有的基本营养成分及其含量范围，以保证能够提供全面均衡的营养支持，同时允许根据特定医疗需求调整某些营养素的比例。

  5. 微生物限量：对成品中的微生物指标如细菌总数、大肠菌群等设定了严格的限量标准，以防止食源性疾病，确保产品卫生安全。

  6. 污染物及添加剂：规定了食品中重金属、农药残留、真菌毒素等污染物的最高限量，以及食品添加剂和营养强化剂的使用原则和具体要求，确保不给消费者带来额外健康风险。

  7. 标签标识：要求产品标签上必须清晰标注食品类型、适用人群、营养成分表、使用方法、储存条件、生产日期、保质期以及必要的警示语等信息，以便消费者和医疗专业人员准确理解和使用。

  8. 生产、包装、运输与贮存：制定了从生产到消费全过程的质量控制措施，确保食品在整个供应链中保持其安全性和营养价值。


如需获取更多详尽信息，请直接参考下方经官方授权发布的权威标准文档。

....

查看全部

  • 现行
  • 正在执行有效
  • 2013-12-26 颁布
  • 2014-07-01 实施
©正版授权
《特殊医学用途配方食品通则》(GB 29922-2013)问答.pdf_第1页
《特殊医学用途配方食品通则》(GB 29922-2013)问答.pdf_第2页
免费预览已结束，剩余14页可下载查看

下载本文档

《特殊医学用途配方食品通则》(GB 29922-2013)问答.pdf-免费下载试读页

文档简介

?GB 29922-20132015-04-15GB 29922-20131/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtmlGB 29923-20132/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtmlGB 29922-2013801CACCodex Stan 180-1991 TheLabeling of and Claims for Food for Special Medical Purpose 21999/21/EC) 3FDA198842012Standard 2.9.52014652002103263/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml123()/FAO/WHOESPGHANEuropean Society of Pediatric GastroenterologyHepatology and NutritionAAPAmerican Academyof Pediatrics)(ESPENEuropean Society forParenteral and Enteral Nutrition)(NASPGHANNorth American Society of Pediatric GastroenterologyHepatology and Nutrition)(ASPENAmericanSociety for Parenteral and Enteral Nutrition)(ANDAcademy of Nutrition and Dietetics)1-10101-33-73-101-101010-1810185065104/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtmlCACA1385/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtmlCOPD1GI1)GIGI552)10%3)30-60%0.3g/100kJ(1.4g/100kcal)4)7mg/100kJ(30mg/100kcal)42mg/100kJ(175 mg/100kcal)1.,WS/T 4292013. 2 ,.,2010:1015. 3 Evert AB, Boucher JL, Cypress M, et al. Nutrition Therapy Recommendations6/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtmlfor the Management of Adults with Diabetes. Diabetes Care, 2013,36: 3827. 4 European Commission. Commission Directive 1999/21/EC of 25 March 1999on Dietary Foods for Special Medical Purposes. Official Journal of the EuropeanCommunities, 1999, 91:2936.2COPDCOPDCOPDMCTn-3COPD1)30%-55%40%MCT10%-20%2)n-3EPADHA1%-6%-1 ASPEN. Board of Directors and The Clinical Guidelines Task Force. Guidelinesfor the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. Journalof Parenteral and Enteral Nutrition, 2002,26(1):64SA. 2Ferreira I, Brooks D, Lacasse Y,et al. Nutritional Intervention in COPD: aSystematic Overview. Chest,2001, 119(2):35363. 3. 2013.,2013, 36(4):110. 4 .:,2013,256. 5 . .:,2013,135. 6 . .2012:491. 7 Cai B, Zhu Y, Ma Yi, et al. Effect of Supplementing a Highfat, LowCarbohydrate Enteral Formula in COPD Patients. Nutrition. 2003 Mar;19(3):22932. 8,.:,2009:633635. 9. (2006). , 2006,44(17):11671177. 10 Simopoulos AP. Essential Fatty Acids in Health and Chronic Disease. Am JClin Nutr,1999,70(3 Suppl): 560S569S.7/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml11 Kompauer I, Demmelmair H, Koletzko B, et al. Association of Fatty Acids inSerum Phospholipids with Lung Function and Bronchial Hyperresponsiveness inAdults. Eur J Epidemiol, 2008;23(3):17590. 12 Shahar E, Folsom AR, Melnick SL, et al. Dietary n3 Polyunsaturated FattyAcids and SmokingRelated Chronic Obstructive Pulmonary Disease. N Engl JMed,1994,331(4):228233. 13 Van der Meij BS, van Bokhorstde van der Schueren MA,Langius JA,et al. n3PUFAs in Cancer, Surgery, and Critical Care: A Systematic Review on Clinical Effects,Incorporation, and Washout of Oral or Enteral Compared with ParenteralSupplementation. Am J Clin Nutr,2011,94(5):124865. 14 World Health Organization. The Global Burden of Disease: 2004 Update.Geneva, Switzerland: WHO, 2008. 15 World Health Organization. Chronic Obstructive Pulmonary Disease, FactSheet No. 215. Geneva, Switzerland:WHO, 2011. 3CKD10.65g/100kJ(2.7g/100kcal)120.8g/100kJ(3.3g/100kcal)100 kJ100 kcalmg53220133mg54020168mg3.316.014.067.0mg1.06.04.025.0mg73030127Ag REN.S.53.8N.S.225.08/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml22.1 N. Cano, E. Fiaccadori, P. Tesinsky, et al. ESPEN Guidelines on EnteralNutrition: Adult Renal Failure. Clinical Nutrition, 2006, 25: 295310.2 Kerri L. Wiggins. Guidelines for Nutrition Care of Renal Patients (ThirdEdition). USA: American Dietetic Association, 2002:10.3 Joel D. The National Kidney Foundation K/DOQI Clinical Practice guidelines forDietary Protein Intake for Chronic Dialysis Patients. American Journal of KidneyDisease, 2001, 38(4): pp S68S73.4 Linda Mccann. Pocket Guide to Nutrition Assessment of the Patient withChronic Kidney Disease (4th Edition). National Kidney Foundation, 2009.5 Lubos Sobatka, .:, 2013: 446447.6 . ,2005, 25(6):437438.7 .:, 2012, P176.8 European Scientific Committee for Food (FortyFirst Series). Opinion on Foodsfor Special Medical Purposes (FSMPS) ,1996 .9 .2008., 2008:96100.10 . . : , 2001,P408.9/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml11 Judith A., VINOD K. BANSAL, et al. Medical Nutrition therapy in ChronicKidney Failure: Integrating Clinical Practice Guidelines. Journal of The AmericanDietetic Association, 2004:404409.41)0.8 g/100kJ (3.3 g/100kcal)2)n-3EPADHA1%-6%,-3)0.12g/100 kJ (0.5g/100kcal)0.04g/100kJ -0.53g/100kJ0.15g/100kcal- 2.22g/100kcal0.03g/100kJ(0.13g/100kcal)1 J. Arends,G. Bodoky, et al. ESPEN Guidelines on Enteral Nutrition : Nonsurgical oncology. Clinical Nutrition, 2006, 25, 245259. 2 , , . .2009, P683. 3 . . :. 2001: 312331. 4 A. Weimann, M. Braga, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including Organ Transplantation. Clinical Nutrition, 2006, 25, 224244. 5 David Allen August, Maureen B. Huhmann, et al. ASPEN. Clinical Guidelines: Nutrition Support Therapy During Adult Anticancer Treatment and in Hematopoietic Cell Transplantation. J Parenter Enteral Nutr, 2009, 33: 472. 6 Ramon Colomer, et al. n3 Fatty Acids, Cancer and Cachexia: a Systematic Review of the Literature. British Journal of Nutrition 2007, 97: 823831. 7 Barbara S van der Meij, et al. n3 PUFAs in Cancer, Surgery, and Critical Case: a Systematic Review on Clinical Effects, Incorporation, and Washout of Oral or Enteral Compared with Parenteral Supplementation. The American Journal of Clinical Nutrition, 2011, 94: 124865. 8 S.RISO, P.ALUFFI, et al. Postoperative Enteral Immunonutrition in Head and Neck Cancer Patients. Clinical Nutrition, 2000, 19 (6): 407412. 10/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml9 Park KG1, Heys SD, Blessing K,et al. Stimulation of Human Breast Cancers by Dietary Larginine. Clin Sci (Lond), 1992, 82 (4):413417. 10 , , . , 2012, 10(7): 18811882. 11 Jiunjie Lin, XiuJuan Chung, et al. A Metaanalysis of Trials Using the Intention to Treat Principle for Glutamine Supplementation in Critically Ill Patients with Burn. Burns, 2013,39:565570.12 Joint FAO/WHO/UNU Expert Consultation. Protein and Amino Acid Requirements in Human Nutrition: Report of a Joint WHO/FAO/UNU Expert Consultation. WHO Technical report series; no. 935. WHO Press, 2002: 138139 5UCCDUCCD1) /240%MCT40%: 1 .2008. , 2008, P6970. 2 H.Lochs, C.Dejong, F.Hammargvist, et al. ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clinical Nutrition, 2006, 25: 260274. 3 James A. Olson, Moshe Shike. Modern Nutrition in Health and Disease (eighth edition). USA: Lea & Febiger, 1994, P10431045. 6GB25596-20101BGB 14880-2012711/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml+1:15:11 Eric H. Kossoff, Beth A. ZupecKania, Per E. Amark, et al. Optimal Clinical Management of Children Receiving the Ketogenic Diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia.2009;50(2):304317. 2 Zahava Turner, Eric H.Kossoff. The Ketogenic and Atkins Diets: Recipes for Seizure Control. Practical gastroenterology.2006;6:5364. 3 Eric H. Kossoff1, HueiShyong Wang. Dietary Therapies for Epilepsy. Biomed J.2013; 36(1):28 4 David N.Ruskin, Susan A.Masino. The Nervous System and Metabolic Dysregulation: Emerging Evidence Converges on Ketogenic Diet Therapy. Frontiers in Neuroscience. 2012;6:112 81)600-1200kcal2)100 kcal3100 kJ100 kcalg2.0N.S.a8.4N.S.g2.0N.S.8.4N.S.A?g RE24.0N.S.100.0N.S.D?g0.10N.S.0.42N.S.Emg ?TE0.40N.S.1.70N.S.B1mg0.03N.S.0.14N.S.B2mg0.05N.S.0.20N.S.B6mg0.08N.S.0.34N.S.B12g0.04N.S.0.17N.S.Cmg1.2N.S.5.0N.S.mg0.44N.S.1.84N.S.12/16GB 29922-2013-.2015/4/15/sps/s3594/201504/f91e9badc4124a3eb98b7ae3829f157e.shtml1 . . :, 2009, P517.2 CODEX. CODEX STAN2031995 Standard for Formula Foods for Use in VeryLow Energy Diets for Weight Reduction. 1995.3 Jeffery I. Mechanick, Robert F. Kushner, Harvey J. Sugerman, et al. AmericanAssociation of Clinical Endocrinologists, The
人人文库> 全部分类> 行业资料 > 各类标准

温馨提示

  • 1. 本站所提供的标准文本仅供个人学习、研究之用，未经授权，严禁复制、发行、汇编、翻译或网络传播等，侵权必究。
  • 2. 本站所提供的标准均为PDF格式电子版文本（可阅读打印），因数字商品的特殊性，一经售出，不提供退换货服务。
  • 3. 标准文档要求电子版与印刷版保持一致，所以下载的文档中可能包含空白页，非文档质量问题。

最新文档

评论

0/150

提交评论